This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Helena Chang Chui, MD; Scott A. Lyness, MA; Eugene Sobel, PhD; Lon S. Schneider, MD

Arch Neurol. 1994;51(7):676-681.

Abstract
Objective
To identify clinical predictors of cognitive decline in Alzheimer's disease.

Design
A cohort of patients was followed up longitudinally and the likelihood of arriving at two cognitive end points was assessed using the Cox proportional hazards model and eight explanatory variables.

Setting
Subjects were chosen from patients examined for memory loss at two medical centers affiliated with the University of Southern California, Los Angeles.

Patients
The sample included 135 patients who met National Institute for Neurological and Communicative Disorders and Stroke—Alzheimer's Disease and Related Disorders Association criteria for probable or definite Alzheimer's disease, had initial Mini-Mental State Examination (MMSE) scores of 14 or greater, and had been seen on at least two occasions.

Main Outcome Measures
The time to reach either of two end points, ie, MMSE score of 8 and a decline of six points on the MMSE, was assessed.

Results
After controlling for initial severity of dementia (eg, by dividing the sample into mild and moderate dementia subgroups or by using the individually defined end point of a six-point decline on the MMSE), the presence at baseline of extrapyramidal signs (risk-hazard ratio, 10.34; 95% confidence interval, 2.76 to 38.68; P=.0005), agitation (risk-hazard ratio, 2.98; 95% confidence interval, 1.35 to 6.61; P=.007),and hallucinations (risk-hazard ratio, 3.85; 95% confidence interval, 1.35 to 11; P=.01) predicted a shorter time to reach an end point.

Conclusions
After controlling for initial severity of dementia, the presence of extrapyramidal signs and behavioral symptoms (agitation and hallucinations) significantly predict faster cognitive decline. These findings may reflect the effects of neuroleptic medication, the presence of underlying diffuse Lewy body disease, or alterations in biogenic amine systems.

Author Affiliations
From the Departments of Neurology (Drs Chui, Sobel, and Schneider), Preventive Medicine (Dr Sobel), and Psychiatry (Mr Lyness and Dr Schneider), University of Southern California School of Medicine, Los Angeles.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Disruptive Behavior as a Predictor in Alzheimer Disease
Scarmeas et al.
Arch Neurol 2007;64:1755-1761.
ABSTRACT | FULL TEXT  

The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration
Ellul et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:233-239.
ABSTRACT | FULL TEXT  

Epidemiology of and Risk Factors for Psychosis of Alzheimer's Disease: A Review of 55 Studies Published From 1990 to 2003
Ropacki and Jeste
Am. J. Psychiatry 2005;162:2022-2030.
ABSTRACT | FULL TEXT  

Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia: Meta-analysis of Randomized Placebo-Controlled Trials
Schneider et al.
JAMA 2005;294:1934-1943.
ABSTRACT | FULL TEXT  

Delusions and Hallucinations Are Associated With Worse Outcome in Alzheimer Disease
Scarmeas et al.
Arch Neurol 2005;62:1601-1608.
ABSTRACT | FULL TEXT  

Motor signs predict poor outcomes in Alzheimer disease
Scarmeas et al.
Neurology 2005;64:1696-1703.
ABSTRACT | FULL TEXT  

Motor signs during the course of Alzheimer disease
Scarmeas et al.
Neurology 2004;63:975-982.
ABSTRACT | FULL TEXT  

Psychosis in Elderly Patients: Classification and Pharmacotherapy
Mintzer and Targum
J Geriatr Psychiatry Neurol 2003;16:199-206.
ABSTRACT  

Effect of Extrapyramidal Signs and Lewy Bodies on Survival in Patients With Alzheimer Disease
Haan et al.
Arch Neurol 2002;59:588-593.
ABSTRACT | FULL TEXT  

Extrapyramidal symptoms and signs in Alzheimer's disease: Pravalence and correlation with the first symptom
Tsolaki et al.
AM J ALZHEIMERS DIS OTHER DEMEN 2001;16:268-278.
ABSTRACT  

The Effects of Age on Rate of Progression of Alzheimer Disease and Dementia With Associated Cerebrovascular Disease
Mungas et al.
Arch Neurol 2001;58:1243-1247.
ABSTRACT | FULL TEXT  

A Method for Estimating Progression Rates in Alzheimer Disease
Doody et al.
Arch Neurol 2001;58:449-454.
ABSTRACT | FULL TEXT  

The Psychotic Phenomenon in Probable Alzheimer's Disease : A Positron Emission Tomography Study
Lopez et al.
J. Neuropsychiatry Clin. Neurosi. 2001;13:50-55.
ABSTRACT | FULL TEXT  

Decline of Language Among Women and Men With Alzheimer's Disease
Hebert et al.
J. Gerontol. B Psychol. Sci. Soc. Sci. 2000;55:354P-361.
ABSTRACT | FULL TEXT  

A Review of the Cognitive and Behavioral Symptoms in Dementia With Lewy Bodies
Simard et al.
J. Neuropsychiatry Clin. Neurosi. 2000;12:425-450.
ABSTRACT | FULL TEXT  

Hallucinations, delusions, and cognitive decline in Alzheimer's disease
Wilson et al.
J. Neurol. Neurosurg. Psychiatry 2000;69:172-177.
ABSTRACT | FULL TEXT  

Progression of Parkinsonism and Loss of Cognitive Function in Alzheimer Disease
Wilson et al.
Arch Neurol 2000;57:855-860.
ABSTRACT | FULL TEXT  

Incidence of and risk factors for hallucinations and delusions in patients with probable AD
Paulsen et al.
Neurology 2000;54:1965-1971.
ABSTRACT | FULL TEXT  

Progression of parkinsonian signs in Alzheimer's disease
Wilson et al.
Neurology 2000;54:1284-1289.
ABSTRACT | FULL TEXT  

An Instrumental Study of the Relationship Between Extrapyramidal Signs and Psychosis in Alzheimer's Disease
Caligiuri and Peavy
J. Neuropsychiatry Clin. Neurosi. 2000;12:34-39.
ABSTRACT | FULL TEXT  

Psychiatric Medication and Abnormal Behavior as Predictors of Progression in Probable Alzheimer Disease
Lopez et al.
Arch Neurol 1999;56:1266-1272.
ABSTRACT | FULL TEXT